Microneedles enable the development of skin-targeted vaccines against coronaviruses and influenza viruses

References

• Alarcon JB, Hartley AW, Harvey NG, Mikszta JA. 2007. Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines. Clin Vaccine Immunol. 14(4):375–381.
   PubMed Web of Science ®Google Scholar
• Al Jarad N, Empey DW, Duckworth G. 1999. Administration of the BCG vaccination using the multipuncture method in schoolchildren: a comparison with the intradermal method. Thorax. 54(9):762–764.
   PubMed Web of Science ®Google Scholar
• Al-Kasasbeh R, Brady AJ, Courtenay AJ, Larrañeta E, McCrudden MTC, O'Kane D, Liggett S, Donnelly RF. 2020. Evaluation of the clinical impact of repeat application of hydrogel-forming microneedle array patches. Drug Deliv Transl Res. 10(3):690–705.
   PubMed Web of Science ®Google Scholar
• Arnou R, Eavis P, Pardo JR, Ambrozaitis A, Kazek MP, Weber F. 2010. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: randomized, controlled, phase III trial. Hum Vaccin. 6(4):346–354.
   PubMed Web of Science ®Google Scholar
• Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek MP, Weber F, Van Damme P. 2009. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine. 27(52):7304–7312.
   PubMed Web of Science ®Google Scholar
• Ashok A, Brison M, LeTallec Y. 2017. Improving cold chain systems: challenges and solutions. Vaccine. 35(17):2217–2223.
   PubMed Web of Science ®Google Scholar
• Bal SM, Caussin J, Pavel S, Bouwstra JA. 2008. In vivo assessment of safety of microneedle arrays in human skin. Eur J Pharm Sci. 35(3):193–202.
   PubMed Web of Science ®Google Scholar
• Bal SM, Ding Z, van Riet E, Jiskoot W, Bouwstra JA. 2010. Advances in transcutaneous vaccine delivery: do all ways lead to Rome? J Control Release. 148(3):266–282. eng.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Klechevsky E, Schmitt N, Morita R, Palucka K, Ueno H. 2009. Harnessing human dendritic cell subsets to design novel vaccines. Ann N Y Acad Sci. 1174:24–32.
   PubMed Web of Science ®Google Scholar
• Bangert C, Brunner PM, Stingl G. 2011. Immune functions of the skin. Clin Dermatol. 29(4):360–376.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Ng'ang'a D, Brandariz KL, Abbink P, et al. 2011. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine. 29(32):5203–5209.
   PubMed Web of Science ®Google Scholar
• Barrett JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, Folegatti PM, Gilbride C, Halkerston R, Hill J, Jenkin D, Stockdale L, Oxford COVID Vaccine Trial Group, et al. 2021. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 27(2):279–288.
   PubMed Web of Science ®Google Scholar
• Beran J, Ambrozaitis A, Laiskonis A, Mickuviene N, Bacart P, Calozet Y, Demanet E, Heijmans S, Van Belle P, Weber F, et al. 2009. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med. 7(1):13.
   PubMed Web of Science ®Google Scholar
• Bonificio A, Ghartey-Tagoe E, Gallorini S, Baudner B, Chen G, Singh P, O'Hagan DT, Kommareddy S. 2015. Fabrication of cell culture-derived influenza vaccine dissolvable microstructures and evaluation of immunogenicity in guinea pigs. Vaccine. 33(25):2930–2938.
   PubMed Web of Science ®Google Scholar
• Boopathy AV, Mandal A, Kulp DW, Menis S, Bennett NR, Watkins HC, Wang W, Martin JT, Thai NT, He Y, et al. 2019. Enhancing humoral immunity via sustained-release implantable microneedle patch vaccination. Proc Natl Acad Sci USA. 116(33):16473–16478.
   PubMed Web of Science ®Google Scholar
• Choi YH, Perez-Cuevas MB, Kodani M, Zhang X, Prausnitz MR, Kamili S, O'Connor SM. 2019. Feasibility of hepatitis B vaccination by microneedle patch: cellular and humoral immunity studies in Rhesus Macaques. J Infect Dis. 220(12):1926–1934.
   PubMed Web of Science ®Google Scholar
• Della Cioppa G, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, Galli C, Groth N, Levin Y, Del Giudice G. 2014. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration. Hum Vaccin Immunother. 10(6):1701–1710. eng.
   PubMed Web of Science ®Google Scholar
• Ding Z, Verbaan FJ, Bivas-Benita M, Bungener L, Huckriede A, van den Berg DJ, Kersten G, Bouwstra JA. 2009. Microneedle arrays for the transcutaneous immunization of diphtheria and influenza in BALB/c mice. J Control Release. 136(1):71–78.
   PubMed Web of Science ®Google Scholar
• Eizenberg P, Booy R, Naser N, Mason G, Stamboulian D, Weber F. 2011. Acceptance of Intanza® 9 μg intradermal influenza vaccine in routine clinical practice in Australia and Argentina. Adv Ther. 28(8):640–649.
   PubMed Web of Science ®Google Scholar
• Ellison TJ, Talbott GC, Henderson DR. 2020. VaxiPatch™, a novel vaccination system comprised of subunit antigens, adjuvants and microneedle skin delivery: An application to influenza B/Colorado/06/2017. Vaccine. 38(43):6839–6848.
   PubMed Web of Science ®Google Scholar
• Esposito S, Daleno C, Picciolli I, Tagliaferri L, Scala A, Prunotto G, Montinaro V, Galeone C, Principi N. 2011. Immunogenicity and safety of intradermal influenza vaccine in children. Vaccine. 29(44):7606–7610.
   PubMed Web of Science ®Google Scholar
• Esser ES, Pulit-Penaloza JA, Kalluri H, McAllister D, Vassilieva EV, Littauer EQ, Lelutiu N, Prausnitz MR, Compans RW, Skountzou I. 2017. Microneedle patch delivery of influenza vaccine during pregnancy enhances maternal immune responses promoting survival and long-lasting passive immunity to offspring. Sci Rep. 7(1):5705.
   PubMedGoogle Scholar
• Fernando GJ, Chen X, Primiero CA, Yukiko SR, Fairmaid EJ, Corbett HJ, Frazer IH, Brown LE, Kendall MA. 2012. Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses. J Control Release. 159(2):215–221.
   PubMed Web of Science ®Google Scholar
• Fernando GJ, Chen X, Prow TW, Crichton ML, Fairmaid EJ, Roberts MS, Frazer IH, Brown LE, Kendall MA. 2010. Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. PLoS One. 5(4):e10266.
   PubMed Web of Science ®Google Scholar
• Fernando GJP, Hickling J, Jayashi Flores CM, Griffin P, Anderson CD, Skinner SR, Davies C, Witham K, Pryor M, Bodle J, et al. 2018. Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™). Vaccine. 36(26):3779–3788.
   PubMed Web of Science ®Google Scholar
• Foged C. 2011. Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems. Ther Deliv. 2(8):1057–1077.
   PubMedGoogle Scholar
• Frenck RW, Jr., Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, Hay CM, Dekker CL, Walter EB, Jr., Cate TR, et al. 2011. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. Vaccine. 29(34):5666–5674.
   PubMed Web of Science ®Google Scholar
• Frew PM, Paine MB, Rouphael N, Schamel J, Chung Y, Mulligan MJ, Prausnitz MR. 2020. Acceptability of an inactivated influenza vaccine delivered by microneedle patch: Results from a phase I clinical trial of safety, reactogenicity, and immunogenicity. Vaccine. 38(45):7175–7181.
   PubMed Web of Science ®Google Scholar
• Fuenmayor J, Gòdia F, Cervera L. 2017. Production of virus-like particles for vaccines. N Biotechnol. 39(Pt B):174–180.
   PubMedGoogle Scholar
• Ghorbani A, Zare F, Sazegari S, Afsharifar A, Eskandari MH, Pormohammad A. 2020. Development of a novel platform of virus-like particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach. New Microbes New Infect. 38:100786.
   PubMed Web of Science ®Google Scholar
• Gill HS, Prausnitz MR. 2007. Coated microneedles for transdermal delivery. J Control Release. 117(2):227–237.
   PubMed Web of Science ®Google Scholar
• Gorse GJ, Falsey AR, Fling JA, Poling TL, Strout CB, Tsang PH. 2013. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age. Vaccine. 31(19):2358–2365.
   PubMed Web of Science ®Google Scholar
• Gorse GJ, Falsey AR, Johnson CM, Morrison D, Fried DL, Ervin JE, Greenberg DP, Ozol-Godfrey A, Landolfi V, Tsang PH. 2013. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age. Vaccine. 31(50):6034–6040.
   PubMed Web of Science ®Google Scholar
• Hirobe S, Azukizawa H, Hanafusa T, Matsuo K, Quan YS, Kamiyama F, Katayama I, Okada N, Nakagawa S. 2015. Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch. Biomaterials. 57:50–58.
   PubMed Web of Science ®Google Scholar
• Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, McKeirnan M, Salem H, Mills G, Reid J, et al. 2008. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis. 198(5):650–658.
   PubMed Web of Science ®Google Scholar
• Hoon Han S, Hee Woo J, Weber F, Joo Kim W, Ran Peck K, Il Kim S, Hwa Choi Y, Myung Kim J. 2013. Immunogenicity and safety of Intanza(®)/IDflu(®) intradermal influenza vaccine in South Korean adults: a multicenter, randomized trial . Hum Vaccin Immunother. 9(9):1971–1977.
   PubMed Web of Science ®Google Scholar
• Hung I, Levin Y, To K, Chan K, Zhang AJ, Li P, Li C, Xu T, Wong TY, Yuen K. 2012. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine. 30 (45):6427–6435.
   PubMed Web of Science ®Google Scholar
• Iversen PL, Bavari S. 2021. Inactivated COVID-19 vaccines to make a global impact. Lancet Infect Dis. 21(6):746–748.
   PubMed Web of Science ®Google Scholar
• Jeong HR, Bae JY, Park JH, Baek SK, Kim G, Park MS, Park JH. 2020. Preclinical study of influenza bivalent vaccine delivered with a two compartmental microneedle array. J Control Release. 324:280–288.
   PubMed Web of Science ®Google Scholar
• Jeong HR, Park S, Park JH, Bae JY, Kim GY, Baek SK, Park MS, Park J-H. 2019. Preparation of H1N1 microneedles by a low-temperature process without a stabilizer. Eur J Pharm Biopharm. 143:1–7.
   PubMed Web of Science ®Google Scholar
• Kang NW, Kim S, Lee JY, Kim KT, Choi Y, Oh Y, Kim J, Kim DD, Park JH. 2021. Microneedles for drug delivery: recent advances in materials and geometry for preclinical and clinical studies. Expert Opinion on Drug Delivery. 18(7):929–947. eng.
   PubMed Web of Science ®Google Scholar
• Kaufmann JR, Miller R, Cheyne J. 2011. Vaccine supply chains need to be better funded and strengthened, or lives will be at risk. Health Aff (Millwood). 30(6):1113–1121.
   PubMed Web of Science ®Google Scholar
• Kermode M. 2004. Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promot Int. 19(1):95–103.
   PubMed Web of Science ®Google Scholar
• Kim E, Erdos G, Huang S, Kenniston TW, Balmert SC, Carey CD, Raj VS, Epperly MW, Klimstra WB, Haagmans BL, et al. 2020. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. EBioMedicine. 55:102743.
   PubMed Web of Science ®Google Scholar
• Kim MC, Lee JW, Choi HJ, Lee YN, Hwang HS, Lee J, Kim C, Lee JS, Montemagno C, Prausnitz MR, et al. 2015. Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection. J Control Release. 210:208–216.
   PubMed Web of Science ®Google Scholar
• Kim YC, Jarrahian C, Zehrung D, Mitragotri S, Prausnitz MR. 2012. Delivery systems for intradermal vaccination. Curr Top Microbiol Immunol. 351:77–112. eng.
   PubMed Web of Science ®Google Scholar
• Kim YC, Park JH, Prausnitz MR. 2012. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 64(14):1547–1568.
   PubMed Web of Science ®Google Scholar
• Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR. 2010. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release. 142(2):187–195.
   PubMed Web of Science ®Google Scholar
• Kim YC, Quan FS, Song JM, Vunnava A, Yoo DG, Park KM, Compans RW, Kang SM, Prausnitz MR. 2010. Influenza immunization with trehalose-stabilized virus-like particle vaccine using microneedles. Procedia Vaccinol. 2(1):17–21.
   Google Scholar
• Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, Prausnitz MR. 2010. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis. 201(2):190–198.
   PubMed Web of Science ®Google Scholar
• Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, Prausnitz MR. 2009. Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine. 27(49):6932–6938.
   PubMed Web of Science ®Google Scholar
• Kim YC, Song JM, Lipatov AS, Choi SO, Lee JW, Donis RO, Compans RW, Kang SM, Prausnitz MR. 2012. Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch. Eur J Pharm Biopharm. 81(2):239–247.
   PubMed Web of Science ®Google Scholar
• Kommareddy S, Baudner BC, Bonificio A, Gallorini S, Palladino G, Determan AS, Dohmeier DM, Kroells KD, Sternjohn JR, Singh M, et al. 2013. Influenza subunit vaccine coated microneedle patches elicit comparable immune responses to intramuscular injection in guinea pigs. Vaccine. 31(34):3435–3441.
   PubMed Web of Science ®Google Scholar
• Kommareddy S, Baudner BC, Oh S, Kwon SY, Singh M, O'Hagan DT. 2012. Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens. J Pharm Sci. 101(3):1021–1027.
   PubMed Web of Science ®Google Scholar
• Korkmaz E, Balmert SC, Sumpter TL, Carey CD, Erdos G, Falo LD. 2021. Microarray patches enable the development of skin-targeted vaccines against COVID-19. Adv Drug Deliv Rev. 171:164–186.
   PubMed Web of Science ®Google Scholar
• Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG, Jacob J, Prausnitz MR, Compans RW, Skountzou I. 2011. Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination. J Infect Dis. 204(4):582–591.
   PubMed Web of Science ®Google Scholar
• Koutsonanos DG, Esser ES, McMaster SR, Kalluri P, Lee JW, Prausnitz MR, Skountzou I, Denning TL, Kohlmeier JE, Compans RW. 2015. Enhanced immune responses by skin vaccination with influenza subunit vaccine in young hosts. Vaccine. 33(37):4675–4682.
   PubMed Web of Science ®Google Scholar
• Koutsonanos DG, Vassilieva EV, Stavropoulou A, Zarnitsyn VG, Esser ES, Taherbhai MT, Prausnitz MR, Compans RW, Skountzou I. 2012. Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep. 2:357.
   PubMed Web of Science ®Google Scholar
• Kuwentrai C, Yu J, Rong L, Zhang BZ, Hu YF, Gong HR, Dou Y, Deng J, Huang JD, X C. 2020. Intradermal delivery of receptor binding domain of SARs-CoV-2 spike protein with dissolvable microneedle to induce humoral and cellular responses in mice. Bioeng Transl Med. 6:e10202.
   Web of Science ®Google Scholar
• Lambert PH, Laurent PE. 2008. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine. 26(26):3197–3208.
   PubMed Web of Science ®Google Scholar
• Lee BY, Bartsch SM, Mvundura M, Jarrahian C, Zapf KM, Marinan K, Wateska AR, Snyder B, Swaminathan S, Jacoby E, et al. 2015. An economic model assessing the value of microneedle patch delivery of the seasonal influenza vaccine. Vaccine. 33(37):4727–4736.
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, Leroux-Roels G. 2008. Seasonal influenza vaccine delivered by intradermal microinjection: a randomised controlled safety and immunogenicity trial in adults. Vaccine. 26(51):6614–6619.
   PubMed Web of Science ®Google Scholar
• Levin Y, Kochba E, Kenney R. 2014. Clinical evaluation of a novel microneedle device for intradermal delivery of an influenza vaccine: are all delivery methods the same? Vaccine. 32(34):4249–4252. eng.
   PubMed Web of Science ®Google Scholar
• Levin Y, Kochba E, Shukarev G, Rusch S, Herrera-Taracena G, van Damme P. 2016. A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly. Vaccine. 34(44):5262–5272.
   PubMed Web of Science ®Google Scholar
• Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC. 2020. Coronavirus vaccine development: from SARS and MERS to COVID-19. J Biomed Sci. 27(1):104.
   PubMed Web of Science ®Google Scholar
• Littauer EQ, Mills LK, Brock N, Esser ES, Romanyuk A, Pulit-Penaloza JA, Vassilieva EV, Beaver JT, Antao O, Krammer F, et al. 2018. Stable incorporation of GM-CSF into dissolvable microneedle patch improves skin vaccination against influenza. J Control Release. 276:1–16.
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, et al. 2021. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet (London, England). 397(10275):671–681.
   PubMed Web of Science ®Google Scholar
• Lundstrom K. 2020. Application of viral vectors for vaccine development with a special emphasis on COVID-19. Viruses. 12(11):1324.
   PubMed Web of Science ®Google Scholar
• Mackett M, Smith GL, Moss B. 1982. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA. 79(23):7415–7419.
   PubMed Web of Science ®Google Scholar
• Malik JA, Mulla AH, Farooqi T, Pottoo FH, Anwar S, Rengasamy KRR. 2021. Targets and strategies for vaccine development against SARS-CoV-2. Biomed Pharmacother. 137:111254.
   PubMed Web of Science ®Google Scholar
• Mellet J, Pepper MS. 2021. A COVID-19 vaccine: big strides come with big challenges. Vaccines (Basel). 9(1):39.
   PubMed Web of Science ®Google Scholar
• Mistilis MJ, Bommarius AS, Prausnitz MR. 2015. Development of a thermostable microneedle patch for influenza vaccination. J Pharm Sci. 104(2):740–749.
   PubMed Web of Science ®Google Scholar
• mLemos-Pérez G, Chávez-Valdés S, González-Formental H, Freyre-Corrales G, Vázquez-Arteaga A, Álvarez-Acevedo B, Ávila-Díaz L, Martínez-Rosales R, Chacón-Quintero Y, Coizeau-Rodríguez E, et al. 2021. Elevated antibody titers in Abdala vaccinees evaluated by Elecsys® anti-SARS-CoV-2 S highly correlate with UMELISA SARS-CoV-2 ANTI RBD, ACE-2 binding inhibition and viral neutralization assays. medRxiv.
   Google Scholar
• Nakatsukasa A, Kuruma K, Okamatsu M, Hiono T, Suzuki M, Matsuno K, Kida H, Oyamada T, Sakoda Y. 2017. Potency of whole virus particle and split virion vaccines using dissolving microneedle against challenges of H1N1 and H5N1 influenza viruses in mice. Vaccine. 35(21):2855–2861.
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Giau VV, Vo TK. 2017. Current advances in transdermal delivery of drugs for Alzheimer's disease. Indian J Pharmacol. 49(2):145–154. eng.
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Nguyen TTD, Tran N-M-A, Vo GV. 2021a. Advances of microneedles in hormone delivery. Biomed Pharmacother. 145:112393.
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Oh Y, Kim Y, Shin Y, Baek S-K, Park J-H. 2021b. Progress in microneedle array patch (MAP) for vaccine delivery. Hum Vaccin Immunother. 17(1):316–327.
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Park JH. 2018. Human studies with microneedles for evaluation of their efficacy and safety. Expert Opin Drug Deliv. 15(3):235–245.
   PubMed Web of Science ®Google Scholar
• Nir Y, Paz A, Sabo E, Potasman I. 2003. Fear of injections in young adults: prevalence and associations. Am J Trop Med Hyg. 68(3):341–344.
   PubMed Web of Science ®Google Scholar
• Norman JJ, Arya JM, McClain MA, Frew PM, Meltzer MI, Prausnitz MR. 2014. Microneedle patches: usability and acceptability for self-vaccination against influenza. Vaccine. 32(16):1856–1862.
   PubMed Web of Science ®Google Scholar
• Ono A, Azukizawa H, Ito S, Nakamura Y, Asada H, Quan YS, Kamiyama F, Katayama I, Hirobe S, Okada N. 2017. Development of novel double-decker microneedle patches for transcutaneous vaccine delivery. Int J Pharm. 532(1):374–383.
   PubMedGoogle Scholar
• O’Shea J, Prausnitz MR, Rouphael N. 2021. Dissolvable microneedle patches to enable increased access to vaccines against SARS-CoV-2 and future pandemic outbreaks. Vaccines (Basel). 9(4):320.
   PubMed Web of Science ®Google Scholar
• Osterholm MT, Kelley NS, Sommer A, Belongia EA. 2012. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 12(1):36–44.
   PubMed Web of Science ®Google Scholar
• Panicali D, Paoletti E. 1982. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA. 79(16):4927–4931.
   PubMed Web of Science ®Google Scholar
• Payne S. 2017. Family Coronaviridae. Viruses.149–158.
   Google Scholar
• Prausnitz MR, Goodson JL, Rota PA, Orenstein WA. 2020. A microneedle patch for measles and rubella vaccination: a game changer for achieving elimination. Curr Opin Virol. 41:68–76.
   PubMed Web of Science ®Google Scholar
• Prymula R, Usluer G, Altinel S, Sichova R, Weber F. 2012. Acceptance and opinions of Intanza/IDflu intradermal influenza vaccine in the Czech Republic and Turkey. Adv Ther. 29(1):41–52. eng.
   PubMed Web of Science ®Google Scholar
• Puig-Barberà J, Natividad-Sancho A, Calabuig-Pérez J, Lluch-Rodrigo JA, Pastor-Villalba E, Martínez-Úbeda S, Díez-Domingo J. 2014. Intradermal and virosomal influenza vaccines for preventing influenza hospitalization in the elderly during the 2011-2012 influenza season: a comparative effectiveness study using the Valencia health care information system. Vaccine. 32(42):5447–5454. eng.
   PubMed Web of Science ®Google Scholar
• Raphael AP, Prow TW, Crichton ML, Chen X, Fernando GJ, Kendall MA. 2010. Targeted, needle-free vaccinations in skin using multilayered, densely-packed dissolving microprojection arrays. Small (Weinheim an Der Bergstrasse, Germany). 6(16):1785–1793.
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Pizza M, Del Giudice G, De Gregorio E. 2014. Vaccines, new opportunities for a new society. Proc Natl Acad Sci USA. 111(34):12288–12293.
   PubMed Web of Science ®Google Scholar
• Rouphael NG, Paine M, Mosley R, Henry S, McAllister DV, Kalluri H, Pewin W, Frew PM, Yu T, Thornburg NJ, et al. 2017. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. Lancet (London, England). 390(10095):649–658.
   PubMed Web of Science ®Google Scholar
• Schepens B, Vos PJ, Saelens X, van der Maaden K. 2019. Vaccination with influenza hemagglutinin-loaded ceramic nanoporous microneedle arrays induces protective immune responses. Eur J Pharm Biopharm. 136:259–266.
   PubMed Web of Science ®Google Scholar
• Sharma A, Tiwari S, Deb MK, Marty JL. 2020. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents. 56(2):106054–106054. eng.
   PubMed Web of Science ®Google Scholar
• Song JM, Kim YC, O E, Compans RW, Prausnitz MR, Kang SM. 2012. DNA vaccination in the skin using microneedles improves protection against influenza. Mol Ther. 20(7):1472–1480.
   PubMed Web of Science ®Google Scholar
• Sullivan SP, Koutsonanos DG, del Pilar Martin M, Lee JW, Zarnitsyn V, Choi S-O, Murthy N, Compans RW, Skountzou I, Prausnitz MR. 2010. Dissolving polymer microneedle patches for influenza vaccination. Nat Med. 16(8):915–920.
   PubMed Web of Science ®Google Scholar
• Taddio A, Ipp M, Thivakaran S, Jamal A, Parikh C, Smart S, Sovran J, Stephens D, Katz J. 2012. Survey of the prevalence of immunization non-compliance due to needle fears in children and adults. Vaccine. 30(32):4807–4812.
   PubMed Web of Science ®Google Scholar
• Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, DiazGranados C, Landolfi V. 2014. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial. Vaccine. 32(21):2507–2517.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Arnou R, Kafeja F, Fiquet A, Richard P, Thomas S, Meghlaoui G, Samson SI, Ledesma E. 2010. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect Dis. 10(1):134.
   PubMedGoogle Scholar
• Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y. 2009. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine. 27(3):454–459. eng.
   PubMed Web of Science ®Google Scholar
• Van Vo G, Bagyinszky E, Park YS, Hulme J, An SSA. 2021. SARS-CoV-2 (COVID-19): Beginning to Understand a New Virus. Adv Exp Med Biol. 1321:3–19.
   Google Scholar
• Vassilieva EV, Kalluri H, McAllister D, Taherbhai MT, Esser ES, Pewin WP, Pulit-Penaloza JA, Prausnitz MR, Compans RW, Skountzou I. 2015. Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature. Drug Deliv Transl Res. 5(4):360–371.
   PubMed Web of Science ®Google Scholar
• Vo VG, Bagyinszky E, Shim K, Park YS, An SSA. 2020. Additional diagnostic testing of the 2019 novel coronavirus (SARS-CoV-2). Mol Cell Toxicol. 16(4):355–353.
   PubMed Web of Science ®Google Scholar
• Vrdoljak A, Allen EA, Ferrara F, Temperton NJ, Crean AM, Moore AC. 2016. Induction of broad immunity by thermostabilised vaccines incorporated in dissolvable microneedles using novel fabrication methods. J Control Release. 225:192–204.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, et al. 2020. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 182(3):713–721.e719.
   PubMed Web of Science ®Google Scholar
• Wang J, Li B, Wu MX. 2015. Effective and lesion-free cutaneous influenza vaccination. Proc Natl Acad Sci USA. 112(16):5005–5010.
   PubMed Web of Science ®Google Scholar
• Warger T, Schild H, Rechtsteiner G. 2007. Initiation of adaptive immune responses by transcutaneous immunization. Immunol Lett. 109(1):13–20.
   PubMed Web of Science ®Google Scholar
• Webby RJ, Webster RG. 2003. Are we ready for pandemic influenza? Science. 302(5650):1519–1522.
   PubMed Web of Science ®Google Scholar
• Webster RG, Govorkova EA. 2014. Continuing challenges in influenza. Ann N Y Acad Sci. 1323(1):115–139.
   PubMedGoogle Scholar
• Weldon WC, Martin MP, Zarnitsyn V, Wang B, Koutsonanos D, Skountzou I, Prausnitz MR, Compans RW. 2011. Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. Clin Vaccine Immunol. 18(4):647–654.
   PubMed Web of Science ®Google Scholar
• Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, et al. 2020. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 324(10):951–960.
   PubMed Web of Science ®Google Scholar
• Yang J, Wang W, Chen Z, Lu S, Yang F, Bi Z, Bao L, Mo F, Li X, Huang Y, et al. 2020. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 586(7830):572–577.
   PubMed Web of Science ®Google Scholar
• Yin Y, Su W, Zhang J, Huang W, Li X, Ma H, Tan M, Song H, Cao G, Yu S, et al. 2021. Separable microneedle patch to protect and deliver DNA nanovaccines against COVID-19. ACS Nano. 15(9):14347–14359.
   PubMed Web of Science ®Google Scholar
• Zehrung D, Jarrahian C, Wales A. 2013. Intradermal delivery for vaccine dose sparing: overview of current issues. Vaccine. 31(34):3392–3395.
   PubMed Web of Science ®Google Scholar
• Zoulek G, Roggendorf M, Deinhardt F, Kunz C. 1986. Different immune responses after intradermal and intramuscular administration of vaccine against tick-borne encephalitis virus. J Med Virol. 19(1):55–61.
   PubMed Web of Science ®Google Scholar